Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Source: SeekingAlpha
2026-03-30 15:22:23 ET
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity March 30, 2026 1:00 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion Inc.
NASDAQ: BMEA
BMEA Trading
-6.57% G/L:
$1.28 Last:
796,784 Volume:
$1.39 Open:
BMEA Latest News
June 05, 2026 07:32:00 pm
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 03, 2026 08:00:00 am
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
May 11, 2026 04:54:51 pm
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
BMEA Stock Data
$94,742,876
57,680,029
0.1%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
